CardioPharma Requests Applications to Investigate the Non-Cardiovascular Benefits of CVD Polypills

Barchart · 3d ago

WILMINGTON, N.C., Dec. 18, 2025 /PRNewswire/ -- CardioPharma, Inc. (the "Company"), a specialty pharmaceutical company focused on combinatorial drug development for cardiovascular diseases, is seeking applications for secondary analyses of existing datasets to investigate the non-cardiovascular (non-CVD) benefits of the CVD polypill (3 or more medications). While the polypill (fixed-dose combination therapy) is primarily intended for CVD prevention and treatment, emerging evidence suggests potential broader health benefits. This funding opportunity invites investigators to explore these effects, determine how much is mediated by CVD improvements versus direct benefits, and evaluate outcomes in both primary and secondary prevention settings.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.